treats Burns, Heart protection during coronary artery bypass grafting, Immune stimulation, Hyperlipidemia, High blood pressure, Weight loss, Antioxidant, Diagnostic procedure, Cancer, Diabetes, Cardiovascular disease, and Infections
SafetyDISCLAIMER: Many complementary techniques are practiced by healthcare professionals with formal training, in accordance with the standards of national organizations. However, this is not universally the case, and adverse effects are possible. Due to limited research, in some cases only limited safety information is available.
Avoid in individuals with a known allergy or hypersensitivity to beta- glucan.
Side Effects and Warnings
Taken by mouth, both yeast and fungal beta- glucans seem to be well tolerated with minimal adverse effects. Beta- glucan has a generally regarded as safe (GRAS) status in the United States. Lentinan and schizophyllan have been safely used in studies. Although not well studied in humans, the co- administration of aspirin and/ or non- steroidal anti- inflammatory drugs (NSAIDs) with beta- glucan can lead to severe gastrointestinal damage resulting in enteric- induced bacterial peritonitis.
There is insufficient information regarding the safety of beta- glucans when used topically (applied on the skin) or subcutaneously (injected under the skin).
Most studies that have evaluated the parenteral use of beta- glucans have used specific forms including PGG- glucan from a proprietary strain of Saccharomyces cerevisiae and certain fungal- derived beta- glucans lentinan and schizophyllan (SPG). PGG- glucan has been safely used in studies when given at the appropriate times under the guidance of a qualified healthcare professional.
When given intravenously, beta- glucans may cause dizziness, headaches, nausea, vomiting, diarrhea, constipation, hives, flushing, rash, high or low blood pressure, or excessive urination.
Beta- glucan has also been associated with inflammatory airway disease and lung inflammation.
Particulate beta- glucan may not be safe. Preliminary evidence suggests intravenous beta- glucans in the microparticulate form may cause serious side effects such as hepatosplenomegaly, granuloma formation, and microembolization.
Use cautiously in AIDS or AIDS- related complex (ARC) patients. Keratoderma of the palms and soles may develop in these patients who are receiving yeast beta- glucans. The condition may begin during the first two weeks of therapy and resolve 2- 4 weeks after discontinuation of beta- glucans.
Pregnancy and Breastfeeding